valoctocogene roxaparvovec在重度血友病A患者中的血液生物分布与载体脱落
在3期GENEr8-1试验中,134例重度血友病A男性接受单次6×10^13 vg/kg的valoctocogene roxaparvovec输注并随访3年,用4种方法检测血液、唾液、粪便、精液和尿液中载体DNA。给药后1至8天载体DNA中位峰值以血液最高,随后持续下降;包膜载体DNA在血浆和精液中≤12周清除,全血和PBMC中载体基因组由非连续向全长转变,提示形成稳定环状游离体;作者认为传播风险低。
要点
- 给药后1至8天载体DNA中位峰值以血液最高,其次为唾液、精液、粪便和尿液,浓度持续下降。
- 包膜载体DNA在血浆和精液中≤12周清除,快于总载体DNA。
- 全血和PBMC中载体基因组由非连续向全长转变,提示核内形成稳定环状游离体。
核心结论
- valoctocogene roxaparvovec为复制缺陷型,加之总载体DNA和包膜载体DNA从脱落基质中持续清除,作者认为传播风险低。
研究设计与样本
- 3期GENEr8-1试验纳入134例重度血友病A男性,单次输注6×10^13 vg/kg valoctocogene roxaparvovec并评估3年。
- 用4种方法检测载体DNA:qPCR测血液、唾液、粪便、精液和尿液中总载体DNA,免疫捕获qPCR测血浆和精液中包膜载体DNA,多色数字PCR测全血和PBMC中载体基因组连续性与ITR融合组装。
- 试验在ClinicalTrials.gov注册号为NCT03370913。
主要发现
- 给药后1至8天载体DNA中位峰值以血液最高,其次为唾液、精液、粪便和尿液,浓度持续下降。
- 包膜载体DNA清除快于总载体DNA,在血浆和精液中≤12周达到清除。
- 全血和PBMC中主要载体基因组形式随时间由非连续转变为全长,提示核细胞内形成稳定环状游离体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Following systemically administered adeno-associated virus gene therapy, vector particles are widely distributed, raising concerns about horizontal or germline vector transmission. Characterization of biodistribution and kinetics of vector DNA in body fluids can address these concerns and provide insights into vector behavior in accessible samples. We investigated biodistribution and vector shedding profile of valoctocogene roxaparvovec in men with severe hemophilia A enrolled in the phase 3 GENEr8-1 trial. Participants (n = 134) received a single 6 × 1013 vector genome (vg)/kg infusion and were assessed over 3 years. Vector DNA was measured using 4 different assays. Total vector DNA was evaluated in blood, saliva, stool, semen, and urine by quantitative polymerase chain reaction (qPCR). Encapsidated vector DNA was measured in plasma and semen with immunocapture-based qPCR. Contiguity of vgs and assembly of inverted terminal repeat fusions were measured in whole blood and peripheral blood mononuclear cells (PBMCs) using multicolor digital PCR. Median peak vector DNA levels observed 1 to 8 days after dosing were highest in blood, followed by saliva, semen, stool, and urine. Concentrations declined steadily. Encapsidated vector DNA cleared faster than total vector DNA, achieving clearance by ≤12 weeks in plasma and semen. Predominant vector genome forms transitioned from noncontiguous to full-length over time in whole blood and PBMCs, indicating formation of stable circularized episomes within nucleated cells. The replication-incompetent nature of valoctocogene roxaparvovec, coupled with steady clearance of total and encapsidated vector DNA from shedding matrices, indicates transmission risk is low. This trial was registered at www.ClinicalTrials.gov as #NCT03370913.
引用
- Agarwal S, Sandza K, Obrochta Moss K, et al. Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A. Blood Adv. 2024. PMID: 39024543. doi:10.1182/bloodadvances.2024013150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。